By Colin Kellaher Lantheus Holdings shares moved lower and hit a new 52-week low on Tuesday after the radiopharmaceutical company said its chairman and chief.
1025 ET – Recent developments in the obesity space should buoy the attractiveness of Viking Therapeutics to big pharma, analysts at William Blair say. In a…
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was